EuroNanoMed III

Basic Information

Description

Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical,
chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological
mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and
therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important
emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the
future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population.
EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals
since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated € 45,5
million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe,
Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account
recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first
joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint
transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the
field. ENM III actions focus on translatability of project results to clinical and industry needs.

H2020 Societal Challenges

Industrial Leadership